UPI SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation of the Board of Directors of Uroplasty, Inc. Regarding the Fairness of the Sale of the Company to Vision-Sciences, Inc.
Business Wire - Wed Dec 24, 11:19AM CST
Levi & Korsinsky is investigating the Board of Directors of Uroplasty, Inc. ("Uroplasty" or "the Company"
VSCI: 0.76 (-0.07), UPI: 2.30 (unch)
UROPLASTY, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Vision-Sciences, Inc.
Business Wire - Tue Dec 23, 10:40AM CST
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Uroplasty, Inc. ("Uroplasty"
VSCI: 0.76 (-0.07), UPI: 2.30 (unch)
UPI SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Uroplasty, Inc. Regarding the Fairness of the Sale of the Company to Vision-Sciences, Inc. -- UPI
PR Newswire - Tue Dec 23, 10:22AM CST
Levi & Korsinsky is investigating the Board of Directors of Uroplasty, Inc. ("Uroplasty" or "the Company"
VSCI: 0.76 (-0.07), UPI: 2.30 (unch)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 11:50AM CST
ADXS: 7.57 (+0.50), SANW: 3.98 (-0.02), ASPS: 33.81 (+4.37), OCN: 14.88 (-0.14), ZAZA: 3.20 (+0.70), SGOC: 0.61 (-0.02), AAMC: 335.99 (-4.00), VOC: 5.60 (-0.09), TECU: 3.59 (-0.14), RDUS: 37.17 (+0.11), IRMD: 12.64 (+0.14), SKYS: 11.05 (-0.95), VSCI: 0.76 (-0.07), CALA: 22.33 (+1.16), REXX: 5.17 (-0.17), CFRX: 3.99 (+0.10), TRXC: 2.79 (+0.03), CHNR: 1.92 (-0.15), CNET: 1.28 (-0.11), DRYS: 1.20 (-0.04)
UROPLASTY, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Mon Dec 22, 11:42AM CST
Rigrodsky & Long, P.A.:
VSCI: 0.76 (-0.07), UPI: 2.30 (unch)
UPI SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Uroplasty, Inc. Regarding the Fairness of the Sale of the Company to Vision-Sciences, Inc.
Business Wire - Mon Dec 22, 9:42AM CST
Levi & Korsinsky is investigating the Board of Directors of Uroplasty, Inc. ("Uroplasty" or "the Company"
VSCI: 0.76 (-0.07), UPI: 2.30 (unch)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 8:17AM CST
OCN: 14.88 (-0.14), SGOC: 0.61 (-0.02), NVGN: 2.40 (-0.09), EXAS: 27.60 (+0.39), TGE: 2.11 (+0.15), CZR: 15.44 (+0.20), ENTA: 49.04 (+0.06), NQ: 4.32 (-0.36), PVG: 5.07 (+0.14), RDUS: 37.17 (+0.11), CANF: 3.70 (+0.01), NG: 2.82 (+0.10), SYN: 1.46 (-0.07), GILD: 91.29 (+1.84), VSCI: 0.76 (-0.07), CNET: 1.28 (-0.11), SVM: 1.25 (+0.09)
Uroplasty and Vision-Sciences to Merge, Creating Innovative Medical Device Company Positioned for Growth
GlobeNewswire - Mon Dec 22, 6:00AM CST
All-Stock Combination Creates New Company with Expanded Product Offerings in Urology
VSCI: 0.76 (-0.07), UPI: 2.30 (unch)
Uroplasty and Vision-Sciences to Merge, Creating Medical Device Company Positioned for Growth
PR Newswire - Mon Dec 22, 6:00AM CST
Uroplasty, Inc. (NASDAQ: UPI) and Vision-Sciences, Inc. (NASDAQ: VSCI) entered into a definitive merger agreement under which the two companies will combine in an all-stock transaction to create a new company expected to generate revenue of approximately $50 million for the fiscal year beginning April 1, 2015.
VSCI: 0.76 (-0.07), UPI: 2.30 (unch)
GERD Awareness Week Puts the Focus on Patient-Centric Diagnostics
GlobeNewswire - Tue Nov 25, 7:52AM CST
The 16th Annual GERD Awareness Week, November 23rd-29th is dedicated to heightening awareness of Gastroesophageal Reflux Disease, or GERD, and encouraging people experiencing GERD-related symptoms to consult their physicians. The week emphasizes educating people on common and uncommon symptoms of GERD and what treatment options they may have when consulting with physicians.
VSCI: 0.76 (-0.07)
Vision-Sciences' (VSCI) CEO Howard Zauberman on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 9:55AM CST
VSCI: 0.76 (-0.07)
Vision-Sciences FQ2 EPS of -$0.03
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:38PM CST
VSCI: 0.76 (-0.07)
Vision-Sciences Reports Financial Results of Second Quarter and First Half Fiscal 2015
GlobeNewswire - Wed Nov 05, 3:37PM CST
Vision-Sciences, Inc. (Nasdaq: VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath technology, today announced financial results for the second quarter and first six months of fiscal (FY) 2015, ended September 30, 2014. Highlights include:
VSCI: 0.76 (-0.07)
Study Reveals Endoscopes May Be Susceptible to Inadequate Sterilization Despite Following Reprocessing Guidelines
GlobeNewswire - Tue Nov 04, 1:44PM CST
A new study published in the Journal of the American Medical Association ("JAMA"
VSCI: 0.76 (-0.07)
Vision-Sciences to Host Second Quarter Fiscal 2015 Results Call
GlobeNewswire - Wed Oct 29, 4:29PM CDT
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R) technology, today announced that the Company will release its financial results for the second quarter fiscal 2015, ended September 30, 2014, after the market closes on Wednesday, November 5, 2014. Howard Zauberman, President and Chief Executive Officer, and Gary Siegel, Vice President, Finance, will host a conference call to discuss the results as follows:
VSCI: 0.76 (-0.07)
Vision-Sciences TNE System Offers Solution for Sedation Concerns
GlobeNewswire - Mon Oct 27, 7:00AM CDT
A Simple Procedure and Novel Technology Provide an Alternative to Sedated Esophageal Exams
VSCI: 0.76 (-0.07)
Vision-Sciences Announces CE Mark and European Launch of Next Generation EndoSheath(R) Bronchoscopy System
GlobeNewswire - Wed Oct 01, 9:21AM CDT
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath technology, today announced the CE Mark approval and European launch of the company's next generation video bronchoscope and EndoSheath technology. The new BRS-5100 video bronchoscope was introduced at the annual ERS (European Respiratory Society) Meeting in Munich, Germany on September 7-10, 2014.
VSCI: 0.76 (-0.07)
Vision-Sciences Introduces Smallest Diameter Flexible Video Laryngoscope to the Ear-Nose-and Throat Market
GlobeNewswire - Mon Sep 22, 7:07AM CDT
The ENT-7000 Offers High Resolution Imaging and Maximum Patient Comfort for Ear Nose and Throat Diagnostics
VSCI: 0.76 (-0.07)
Vision-Sciences Reports First Quarter Fiscal 2015 Results
GlobeNewswire - Mon Aug 04, 3:30PM CDT
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath technology, today announced financial results for the first quarter of fiscal 2015, ended June 30, 2014.
VSCI: 0.76 (-0.07)